Loading quotes...
Forecast
The analysts' average price target is âŹ20.26 (+54.07%). The median is âŹ14.46 (+9.96%).
| Buy |
Â
8 |
| Hold |
Â
1 |
| Sell |
Â
1 |
News Go to news feed
Hutchmed share rises 5% after positive phase-III results for lung cancer drug
Hutchmed reported that the Phase-III study SAFFRON for ORPATHYS (Savolitinib) in combination with TAGRISSO (Osimertinib) significantly improved both progression-free survival and overall survival in patients with MET-driven, EGFR-resistant non-small-cell lung cancer. The stock climbed intraday by about 5% to HK$20.14, reaching its highest level since May 11. The global study included 338 patients; the result strengthens the case for worldwide regulatory filings and could extend the combinationâs commercial prospects beyond China. » More on de.investing.com
HUTCHMED: China grants conditional approval for gastric cancer drug ORPATHYS, shares jump
Chinaâs drug regulator has granted conditional approval for ORPATHYS (savolitinib) from HUTCHMED for the treatment of METâamplified advanced gastric cancer and gastroesophageal junction adenocarcinoma. The approval is based on a Phase II study showing an objective response rate of 32.3% and secondary endpoints including a disease control rate of 63.1% and a median progressionâfree survival of 4.0 months. ORPATHYS is the first approval of a selective MET inhibitor for this patient group in China, is being developed jointly with AstraZeneca, and is already listed on the national reimbursement list. After the announcement, HUTCHMEDâs shares rose sharply (around +6.5%). » More on de.investing.com
HUTCHMED: ORPATHYS conditionally approved in China for METâamplified gastric cancer
Chinaâs drug regulator granted HUTCHMED conditional approval for ORPATHYS (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification after at least two prior systemic therapies. The approval is based on a Phase II study in China showing an objective response rate of 32.3%, a disease control rate of 63.1% and a median progressionâfree survival of 4.0 months. ORPATHYS is the first selective MET inhibitor approved in China for this indication; MET amplifications affect about 4â6% of patients (roughly 18,000 cases annually). The drug was coâdeveloped with AstraZeneca and is already listed on Chinaâs reimbursement list. » More on de.investing.com
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 121.92m | 3.50% |
| Gross profit | 20.74m | 55.59% |
| Net profit | 6.98m | 96.38% |
| EBITDA | 3.48m | 214.94% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ2.2bn |
Number of shares | 176.22m |
52-week high/low | âŹ14.53 - âŹ8.69 |
| Dividends | No |
Beta | 0.43 |
P/E ratio | 153.47 |
PEG ratio | -1.59 |
P/B ratio | 1.95 |
P/S ratio | 4.49 |
Company profile
HUTCHMED (China) Limited erforscht, entwickelt und vermarktet gezielte Therapeutika und Immuntherapien fĂŒr Krebs und immunologische Erkrankungen in Hongkong und international. Das Unternehmen ist in den Segmenten Onkologie/Immunologie und Sonstige Ventures tĂ€tig. Das Unternehmen entwickelt Savolitinib, einen Hemmstoff fĂŒr nicht-kleinzelligen Lungenkrebs (NSCLC), papillĂ€res und Nierenzellkarzinom, kolorektales Karzinom (CRC) und Magenkrebs (GC); und Fruquintinib, einen Hemmstoff fĂŒr CRC, Brustkrebs, GC, Endometriumkarzinom (EMC), NSCLC, hepatozellulĂ€res Karzinom und gastrointestinale und solide Tumoren. Es entwickelt auch Surufatinib, einen Hemmstoff fĂŒr neuroendokrine Tumore (NET), pankreatische NET, nicht-pankreatische NET, Gallenwegskrebs, Sarkom, neuroendokrine Neoplasmen, Speiseröhrenkrebs, kleinzelligen Lungenkrebs, GC, SchilddrĂŒsenkrebs, EMC, NSCLC und solide Tumore; HMPL-523, ein Milz-Tyrosinkinase-Hemmer fĂŒr hĂ€matologische Krebserkrankungen und bestimmte chronische Immunerkrankungen; und HMPL-689 fĂŒr die Isoform PI3Kd (Phosphoinositid-3'-Kinase delta). DarĂŒber hinaus entwickelt das Unternehmen Tazemetostat, einen Hemmstoff von EZH2 zur Behandlung bestimmter epitheloider Sarkome und follikulĂ€rer Lymphome, sowie HMPL-306, einen Hemmstoff fĂŒr hĂ€matologische Malignome, Gliome und solide Tumore; HMPL-760, ein Bruton-Tyrosinkinase-Inhibitor; HMPL-453, ein Inhibitor fĂŒr intrahepatische Cholangiokarzinome; HMPL-295 fĂŒr solide Tumore; HMPL-653 fĂŒr metastasierende solide Tumore und tenosynoviale Riesenzelltumore; und die Inhibitoren Epitinib (HMPL-813) und Theliatinib (HMPL-309). Das Unternehmen hat Kooperationsvereinbarungen mit AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd, Innovent Biologics Co, Inc. und Genor Biopharma Co. Ltd, Shanghai Junshi Biosciences Co. Ltd. und Epizyme, Inc. Das Unternehmen war frĂŒher unter dem Namen Hutchison China MediTech Limited bekannt und Ă€nderte im Mai 2021 seinen Namen in HUTCHMED (China) Limited. Das Unternehmen wurde im Jahr 2000 gegrĂŒndet und hat seinen Hauptsitz in Central, Hongkong.
| Name | HUTCHMED (CHINA) LS-,10 Aktie |
| CEO | Chig Fung Cheng |
| Headquarters | Hong Kong,
Hong Kong |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 16/03/2016 |
| Employees | 1,796 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | HCM |
Frankfurt | H7T1.F |
DĂŒsseldorf | H7T1.DU |
London | 0J7G.L |
